Personalis, Inc.
Personalis develops, markets and sells genomic testing services for physicians treating cancer patients, pharmaceutical and biopharmaceutical companies, diagnostic companies, and population sequencing initiatives. It operates as one business segment and performs testing in a CLIA-certified, CAP-accredited laboratory at its 100,000 square foot headquarters in Fremont, California. Its services include NeXT Personal Dx for detecting residual or recurrent cancer and monitoring response to therapy, NeXT Dx for tumor profiling to help guide therapy selection and identify clinical trials, and NeXT Personal and ImmunoID NeXT for pharmaceutical research and clinical trials. Personalis also provides whole exome sequencing for diagnostic companies and whole genome sequencing for research and population sequencing projects. It sells through a small direct sales force organized by geography and through a co-commercialization arrangement with Tempus. Its customers include cancer patients, companies, universities, non-profits and government entities.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $PSNL in the last 30 days.
See all $PSNL insider activity →Personalis (PSNL) announced a $50M investment from Merck (MRK) at $3.56 per share, giving Merck a 16.5% stake. The company also extended its collaboration with Moderna (MRNA) for its ImmunoID NeXT Platform in cancer therapy development.
ARK ETFs sold 17,053 shares of Shopify (SHOP) and bought 199,698 shares of Scribe Therapeutics (SCTX) on October 21st, 2026. Other notable trades included selling Personalize (PSNL) and buying Intuitive Surgical (ISRG) and X-Energy (XE).
Personalis, Inc. (PSNL) introduced a Real-Time Variant Tracker for its NeXT Personal MRD report, tracking clinically relevant variants. The feature will be commercially available starting October 20, 2026, according to the company. The update expands the MRD platform's capabilities, focusing on clinically actionable ctDNA monitoring.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PSNL (Personalis, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PSNL coverage spans financial news, mergers & acquisitions and corporate actions.
Positive catalyst as fresh capital and strategic partnership may boost share price.
Possible downside pressure from fund divestiture.
The new tracker could drive incremental revenue if adopted by physicians and payers.
Ark Invest, led by Cathie Wood, increased stakes in AI and biotech, buying $25.9M of CoreWeave, $24.4M of Meta, and $17.6M of Recursion. It also acquired $16.3M of Cerebras.
Potential downward pressure as a large holder exits.
AlphAI scores every news story that mentions PSNL with an AI model for sentiment and relevance, and aggregates insider trades from Personalis, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Personalis (PSNL) announced a $50M investment from Merck (MRK) at $3.56 per share, giving Merck a 16.5% stake. The company also extended its collaboration with Moderna (MRNA) for its ImmunoID NeXT Platform in cancer therapy development.
2 min readARK ETFs sold 17,053 shares of Shopify (SHOP) and bought 199,698 shares of Scribe Therapeutics (SCTX) on October 21st, 2026. Other notable trades included selling Personalize (PSNL) and buying Intuitive Surgical (ISRG) and X-Energy (XE).
2 min readPersonalis, Inc. (PSNL) introduced a Real-Time Variant Tracker for its NeXT Personal MRD report, tracking clinically relevant variants. The feature will be commercially available starting October 20, 2026, according to the company. The update expands the MRD platform's capabilities, focusing on clinically actionable ctDNA monitoring.
1 min readArk Invest, led by Cathie Wood, increased stakes in AI and biotech, buying $25.9M of CoreWeave, $24.4M of Meta, and $17.6M of Recursion. It also acquired $16.3M of Cerebras.
1 min readARK ETFs sold 670,746 shares of Personalised (PSNL) for $10.7M, bought 254,668 shares of Freenome (FRNM) for $3.1M, sold 59,477 shares of CareDx (CDNA) for $4M, and bought 29,416 shares of Scribe Therapeutics (SCTX) for $609K. These trades indicate ARK's strategic portfolio adjustments.
1 min readARK ETFs bought CoreWeave (CRWV) and Kratos (KTOS) for $19.68M and $9.15M, respectively, and sold Robinhood (HOOD) and Personalis (PSNL) for $17.01M and $12.01M. Other trades included Teradyne (TER), Recursion (RXRX), and smaller positions in several other companies.
2 min readPerson has agreed to a merger with Tempus, becoming a wholly owned subsidiary. The HSR waiting period expired on Oct 2, 2026. The deal requires stockholder approval and other conditions. Tempus filed relevant documents with the SEC.
1 min readPersonalis, Inc. (PSNL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on July 20, 2026, Personalis, Inc., a Delaware corporation (“ Personalis ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Tempus AI, Inc., a Nevada corporation (“ Tempus ” or “ Par
2 min readPersonalis (PSNL) stock fell 2.8% after BTIG downgraded it to Neutral, removing the $16.25 price target. The analyst believes the Tempus AI acquisition will close at the agreed price, with little chance of improvement. BTIG also concluded that the board prioritized deal speed over a higher bid, despite interest from Merck. The S&P 500 and other indices rose, but Personalis' decline was stock-specific.
1 min readPersonalis CFO Aaron Tachibana sold 2,931 shares at $16.22 each, totaling $47,540, to cover tax obligations. Tempus AI agreed to acquire Personalis for $1.5B, offering $16.25 per share, a 6% premium. Needham downgraded Personalis to Hold, raised its target to $17, and reiterated a Buy rating for Tempus AI with a $75 target. Personalis received UK regulatory clearance for its NeXT Personal Dx test.
2 min read
